Opko Health, Inc. · NASDAQ:OPK
Opko Health — Merger or Acquisition (January 2013)
19 slides from Opko Health's merger presentation, Jan 9, 2013
Slide 1: Corporate Presentation January 2013
Exhibit 99.2 Corporate Presentation January 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements and information included in this presentation are “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 (PSLRA), including expectations regarding (1) the market opportunity and growth potential of the CKD patient populat
Slide 3: A clinical stage specialty pharmaceutical company focused on Chronic Kidney Disease
A clinical stage specialty pharmaceutical company focused on Chronic Kidney Disease 2 © Cytochroma 2011
Slide 4: Company Overview
Company Overview Mission: To Improve People’s Lives by Treating and Preventing Clinical Consequences of Vitamin D Insufficiency and Secondary Hyperparathyroidism 3 © Cytochroma 2011
Slide 5: Company Overview
Company Overview Mission: To Improve People’s Lives by Treating and Preventing Clinical Consequences of Vitamin D Insufficiency and Secondary Hyperparathyroidism 4 © Cytochroma 2011
Slide 6: Cytochroma Product Pipeline
Cytochroma Product Pipeline A clinical-stage specialty pharmaceutical company focused on CKD Territorial Product Indication Research Preclinical Phase I Phase II Phase III Rights CTAP101 Low 25D and SHPT* Worldwide Capsules (CKD Stage 3-4 Patients) Fermagate Hyperphosphatemia Worldwide Tablets (CKD
Slide 7: Vitamin D: Central To SHPT Etiology & Treatment
Vitamin D: Central To SHPT Etiology & Treatment CalcimimeticTherapies Ca-Based Binder Therapies Ca-Free Binder Therapies Hyperphosphatemia Hypocalcemia Fermagate Tablets CYP24 Inhibitor Parathyroid Target Tissues hormone (Parathyroid gland) Therapies Vitamin D Vitamin D Inactivated Vitamin D Liver E
Slide 8: Market Opportunity: Chronic Kidney Disease (U.S.)
Market Opportunity: Chronic Kidney Disease (U.S.) The CKD patient population is large and growing as a result of cardiovascular disease, obesity and diabetes Current U.S. sales are derived predominantly from Stage 5 CKD: • Approximately $1.5 billion for SHPT therapies • Approximately $0.8 billion fo
Slide 9: CTAP101 Capsules
CTAP101 Capsules Product Overview Clinical Status Modified-release (MR) formulation of 25D* Phase 2b study complete and reported strong Safe and effective treatment for elevated PTH efficacy and safety data (SHPT) associated with low 25D levels in Stages High proportion of patients achieved increase
Slide 10: Limitations of Existing Therapies
Limitations of Existing Therapies Company Product Use Limitations Limited systemic availability due to sequestering Ergocalciferol Capsules Nutritional Vitamin D: in fat tissue (Drisdol) SHPT and Low 25D Inconsistent effects, dependant on GI functionality Ergocalciferol Drops (Off-label) and bile pr
Slide 11: The Great Unmet Medical Need
The Great Unmet Medical Need Nephrologists report a significant need for a therapy that can raise serum 25D levels and suppress plasma PTH levels Nearly 60% of nephrologists frequently or always measure 25D levels in CKD Stage 3-4 patients Nearly 90% of nephrologists use nutritional vitamin D in CKD
Slide 12: CTAP101: Significant Commercial Opportunity
CTAP101: Significant Commercial Opportunity Low serum 25D and high plasma PTH are prevalent in CKD Stage 3-4 patients • 8.0M CKD Stage 3-4 patients in the U.S. 4.0M patients with low serum 25D and high plasma PTH ~1.0M patients seen by nephrologist ~1.0M patients seen by endocrinologist Existing tre
Slide 13: CTAP101: Corrects Vitamin D Insufficiency
CTAP101: Corrects Vitamin D Insufficiency 12 © Cytochroma 2011
Slide 14: CTAP101: Corrects SHPT (Elevated Plasma iPTH)
CTAP101: Corrects SHPT (Elevated Plasma iPTH) 13 © Cytochroma 2011
Slide 15: CTAP101 Capsules: Phase 2b Summary
CTAP101 Capsules: Phase 2b Summary Repeat dose proof of concept CTAP101 Capsules reliably increase serum 25D and reduce plasma PTH CTAP101 Capsules are safe in CKD Stage 3-4 patients CTAP101’s efficacy and safety compare favorably to competing products No competing products can consistently normaliz
Slide 16: CTAP101: Phase 3 and NDA Timelines
CTAP101: Phase 3 and NDA Timelines 2012 2013 2014 2015 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Dose ranging SPA TG Mouse Carcinogenicity Study CL-3001 Data SPA CL-3001 trial CL-3002 Data CL-3002 trial Open Label Extension NDA NDA Safety Filing Update NDA Approval © Cytochroma 2011
Slide 17: CTAP101-CL-3001 & CL-3002 Combined Site Map
CTAP101-CL-3001 & CL-3002 Combined Site Map = Selected investigator sites for study 3001 (33 Sites) = Selected investigator sites for study 3002 (30 Sites) © Cytochroma 2011
Slide 18: Corporate Highlights
Corporate Highlights CTAP101 Capsules is a Highly Differentiated Lead Asset • First-in-class modified-release vitamin D prohormone that both corrects vitamin D insufficiency and controls SHPT* in patients with stage 3 or stage 4 CKD No current therapy can reliably restore adequate serum 25D** and su
Slide 19: Corporate Presentation January 2013
Corporate Presentation January 2013